Plasma metabolites associated with colorectal cancer stage: Findings from an international consortium

Anne J M R Geijsen, Eline H van Roekel, Fränzel J B van Duijnhoven, David Achaintre, Thomas Bachleitner-Hofmann, Andreas Baierl, Michael M Bergmann, Jürgen Boehm, Martijn J L Bours, Hermann Brenner, Stéphanie O Breukink, Stefanie Brezina, Jenny Chang-Claude, Esther Herpel, Johannes H W de Wilt, Audrey Gicquiau, Biljana Gigic, Tanja Gumpenberger, Bibi M E Hansson, Michael Hoffmeister, Andreana N Holowatyj, Judith Karner-Hanusch, Pekka Keski-Rahkonen, Eric T P Keulen, Janna L Koole, Gernot Leeb, Jennifer Ose, Peter Schirmacher, Martin A Schneider, Petra Schrotz-King, Anton Stift, Arve Ulvik, F Jeroen Vogelaar, Evertine Wesselink, Moniek van Zutphen, Andrea Gsur, Nina Habermann, Ellen Kampman, Augustin Scalbert, Per M Ueland, Alexis B Ulrich, Cornelia M Ulrich, Matty P Weijenberg, Dieuwertje E Kok, Anne J M R Geijsen, Eline H van Roekel, Fränzel J B van Duijnhoven, David Achaintre, Thomas Bachleitner-Hofmann, Andreas Baierl, Michael M Bergmann, Jürgen Boehm, Martijn J L Bours, Hermann Brenner, Stéphanie O Breukink, Stefanie Brezina, Jenny Chang-Claude, Esther Herpel, Johannes H W de Wilt, Audrey Gicquiau, Biljana Gigic, Tanja Gumpenberger, Bibi M E Hansson, Michael Hoffmeister, Andreana N Holowatyj, Judith Karner-Hanusch, Pekka Keski-Rahkonen, Eric T P Keulen, Janna L Koole, Gernot Leeb, Jennifer Ose, Peter Schirmacher, Martin A Schneider, Petra Schrotz-King, Anton Stift, Arve Ulvik, F Jeroen Vogelaar, Evertine Wesselink, Moniek van Zutphen, Andrea Gsur, Nina Habermann, Ellen Kampman, Augustin Scalbert, Per M Ueland, Alexis B Ulrich, Cornelia M Ulrich, Matty P Weijenberg, Dieuwertje E Kok

Abstract

Colorectal cancer is the second most common cause of cancer-related death globally, with marked differences in prognosis by disease stage at diagnosis. We studied circulating metabolites in relation to disease stage to improve the understanding of metabolic pathways related to colorectal cancer progression. We investigated plasma concentrations of 130 metabolites among 744 Stages I-IV colorectal cancer patients from ongoing cohort studies. Plasma samples, collected at diagnosis, were analyzed with liquid chromatography-mass spectrometry using the Biocrates AbsoluteIDQ™ p180 kit. We assessed associations between metabolite concentrations and stage using multinomial and multivariable logistic regression models. Analyses were adjusted for potential confounders as well as multiple testing using false discovery rate (FDR) correction. Patients presented with 23, 28, 39 and 10% of Stages I-IV disease, respectively. Concentrations of sphingomyelin C26:0 were lower in Stage III patients compared to Stage I patients (pFDR < 0.05). Concentrations of sphingomyelin C18:0 and phosphatidylcholine (diacyl) C32:0 were statistically significantly higher, while citrulline, histidine, phosphatidylcholine (diacyl) C34:4, phosphatidylcholine (acyl-alkyl) C40:1 and lysophosphatidylcholines (acyl) C16:0 and C17:0 concentrations were lower in Stage IV compared to Stage I patients (pFDR < 0.05). Our results suggest that metabolic pathways involving among others citrulline and histidine, implicated previously in colorectal cancer development, may also be linked to colorectal cancer progression.

Keywords: colorectal cancer; disease stage; epidemiology; metabolomics; plasma metabolites.

© 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.

Figures

Figure 1
Figure 1
Flowchart of the total study population.
Figure 2
Figure 2
Top 10 plasma metabolites associated with colorectal cancer stages, ranked by p‐value. Black bars and symbols represent metabolites statistically significantly associated with stage after FDR correction (pFDR ≤ 0.05). Gray bars and symbols represent metabolites not statistically significantly associated with stage after FDR correction (pFDR > 0.05). (a). Top 10 plasma metabolites associated with Stage II (n = 212) colorectal cancer compared to Stage I (n = 168), ranked by pFDR. (b). Top 10 plasma metabolites associated with Stage III (n = 290) colorectal cancer compared to Stage I (n = 168), ranked by pFDR. (c) Top 10 plasma metabolites associated with Stage IV (n = 74) colorectal cancer compared to Stage I (n = 168), ranked by pFDR; Scale is logarithmic, pFDR: p‐value corrected for FDR.

References

    1. Mehrkhani F, Nasiri S, Donboli K, et al. Prognostic factors in survival of colorectal cancer patients after surgery. Colorectal Dis 2009;11:157–61.
    1. Siegel R, DeSantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin 2014;64:104–17.
    1. Wishart D, Mandal R, Stanislaus A, et al. Cancer metabolomics and the human metabolome database. Metabolites 2016;6:10.
    1. Williams MD, Reeves R, Resar LS, et al. Metabolomics of colorectal cancer: past and current analytical platforms. Anal Bioanal Chem 2013;405:5013–30.
    1. Denkert C, Budczies J, Weichert W, et al. Metabolite profiling of human colon carcinoma–deregulation of TCA cycle and amino acid turnover. Mol Cancer 2008;7:72.
    1. Farshidfar F, Weljie AM, Kopciuk KA, et al. A validated metabolomic signature for colorectal cancer: exploration of the clinical value of metabolomics. Br J Cancer 2016;115:1–10.
    1. Geijsen AJMR, Brezina S, Keski‐Rahkonen P, et al. Plasma metabolites associated with colorectal cancer: a discovery‐replication strategy. Int J Cancer 2019;145:1221–31.
    1. Nishiumi S, Kobayashi T, Ikeda A, et al. A novel serum metabolomics‐based diagnostic approach for colorectal cancer. PLoS One 2012;7:e40459.
    1. Farshidfar F, Weljie AM, Kopciuk K, et al. Serum metabolomic profile as a means to distinguish stage of colorectal cancer. Genome Med 2012;4:42.
    1. Vahabi F, Sadeghi S, Arjmand M, et al. Staging of colorectal cancer using serum metabolomics with 1HNMR spectroscopy. Iran J Basic Med Sci 2017;20:835.
    1. Sirniö P, Väyrynen JP, Klintrup K, et al. Alterations in serum amino‐acid profile in the progression of colorectal cancer: associations with systemic inflammation, tumour stage and patient survival. Br J Cancer 2018;120:238–46.
    1. Guertin KA, Moore SC, Sampson JN, et al. Metabolomics in nutritional epidemiology: identifying metabolites associated with diet and quantifying their potential to uncover diet‐disease relations in populations. Am J Clin Nutr 2014;100:208–17.
    1. Yu Z, Zhai G, Singmann P, et al. Human serum metabolic profiles are age dependent. Aging Cell 2012;11:960–7.
    1. Sampson JN, Boca SM, Shu XO, et al. Metabolomics in epidemiology: sources of variability in metabolite measurements and implications. Cancer Epidemiol Biomarkers Prev 2013;22:631–40.
    1. Winkels RM, Heine‐Bröring RC, Van Zutphen M, et al. The COLON study: colorectal cancer: longitudinal, observational study on nutritional and lifestyle factors that may influence colorectal tumour recurrence, survival and quality of life. BMC Cancer 2014;14:374.
    1. van Roekel EH, Bours MJ, de Brouwer CP, et al. The applicability of the international classification of functioning, disability and health to study lifestyle and quality of life of colorectal cancer survivors. Cancer Epidemiol Biomarkers Prev 2014;23:1394–405.
    1. Ulrich CM, Gigic B, Bohm J, et al. The ColoCare study ‐ a paradigm of transdisciplinary science in colorectal cancer outcomes. Cancer Epidemiol Biomarkers Prev 2018;28:591–601.
    1. Li Y, Wang J, Ma X, et al. A review of neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Int J Biol Sci 2016;12:1022–31.
    1. Brierley JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. Hoboken, New Jersey: John Wiley & Sons, 2016.
    1. Siskos AP, Jain P, Römisch‐Margl W, et al. Interlaboratory reproducibility of a targeted metabolomics platform for analysis of human serum and plasma. Anal Chem 2016;89:656–65.
    1. Carayol M, Licaj I, Achaintre D, et al. Reliability of serum metabolites over a two‐year period: a targeted metabolomic approach in fasting and non‐fasting samples from EPIC. PLoS One 2015;10:e0135437.
    1. van Roekel EH, Trijsburg L, Assi N, et al. Circulating metabolites associated with alcohol intake in the European Prospective Investigation into Cancer and Nutrition cohort. Nutrients 2018;10:E654.
    1. Fages A, Ferrari P, Monni S, et al. Investigating sources of variability in metabolomic data in the EPIC study: the principal component partial R‐square (PC‐PR2) method. Metabolomics 2014;10:1074–83.
    1. Assi N, Thomas DC, Leitzmann M, et al. Are metabolic signatures mediating the relationship between lifestyle factors and hepatocellular carcinoma risk? Results from a nested case–control study in EPIC. Cancer Epidemiol Biomarkers Prev 2018;27:531–40.
    1. DerSimonian R, Laird N. Meta‐analysis in clinical trials. Control Clin Trials 1986;7:177–88.
    1. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta‐analysis. Stat Med 2002;21:1539–58.
    1. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta‐analyses. BMJ 2003;327:557–60.
    1. Cambiaghi A, Ferrario M, Masseroli M. Analysis of metabolomic data: tools, current strategies and future challenges for omics data integration. Brief Bioinform 2016;18:498–510.
    1. Higgins J, Green S. Cochrane handbook for systematic reviews of interventions, vol. 5 Hoboken, New Jersey: John Wiley & Sons, 2011. 1–492.
    1. Barzał JA, Szczylik C, Rzepecki P, et al. Plasma citrulline level as a biomarker for cancer therapy‐induced small bowel mucosal damage. Acta Biochim Pol 2014;61:615–31.
    1. Urea Cycle MY. In: Siegel GJAB, Albers RW, et al., eds Basic neurochemistry: molecular, cellular and medical aspects, 6th edn. Philadelphia, PA: Lippincott‐Raven, 1999.
    1. Swanson TA, Kim SA, Glucksman MJ. Biochemistry, Molecular Biology & Genetics, 5th edn. Wolters Kluwer: Baltimore, MD, 2010.
    1. Brown DG, Rao S, Weir TL, et al. Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab 2016;4:E11.
    1. van de Poll MC, Siroen MP, van Leeuwen PA, et al. Interorgan amino acid exchange in humans: consequences for arginine and citrulline metabolism. Am J Clin Nutr 2007;85:167–72.
    1. Liesenfeld D, Habermann N, Toth R, et al. Changes in urinary metabolic profiles of colorectal cancer patients enrolled in a prospective cohort study (ColoCare). Metabolomics 2015;11:998–1012.
    1. Jaremek M, Yu Z, Mangino M, et al. Alcohol‐induced metabolomic differences in humans. Transl Psychiatry 2013;3:e276.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅